Wirth M, Manseck A, Helke C
Klinik und Poliklinik für Urologie, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden.
Urologe A. 1998 Mar;37(2):135-7. doi: 10.1007/s001200050159.
In the last years radical retropubic prostatectomy has become the treatment of choice for locally confined prostate cancer (PCa). However, in the literature local recurrence is described in 4-23% of patients with clinical stage T1-2 prostate cancer and in 43% of patients with clinical stage T3 respectively. The problem is further aggravated that postoperatively raised PSA values are detected in 6-8% of patients with locally confined prostate cancer indicating either local residual tumor or systemic disease. Current datas show that wait-and-watch appears to be the best option for patients with locally confined prostate cancer and positive margins. In case of persistent or raising PSA-values following prostatectomy without detectable local recurrence or metastasis mere local therapy cannot be recommended. Primary radiotherapy should be considered in cases with confirmed clinical local recurrence without distant metastasis. Further prospective and randomized trials have to be initiated to identify the patients with positive margins who will benefit from adjuvant treatment.
在过去几年中,根治性耻骨后前列腺切除术已成为局限性前列腺癌(PCa)的首选治疗方法。然而,文献报道临床分期为T1-2前列腺癌的患者局部复发率为4%-23%,临床分期为T3的患者局部复发率为43%。更严重的问题是,6%-8%局限性前列腺癌患者术后PSA值升高,提示存在局部残留肿瘤或全身性疾病。目前数据表明,对于切缘阳性的局限性前列腺癌患者,等待观察似乎是最佳选择。前列腺切除术后若PSA值持续升高或上升,且未发现局部复发或转移,则不建议单纯进行局部治疗。对于确诊为临床局部复发且无远处转移的患者,应考虑进行原发性放疗。必须开展进一步的前瞻性随机试验,以确定哪些切缘阳性患者将从辅助治疗中获益。